Meletios Α. Dimopoulos

Research interests

Publications

• Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2020.11.014

• Hematological findings and complications of COVID ‐19

  American Journal of Hematology · 2020 · https://doi.org/10.1002/ajh.25829

• Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

  Leukemia · 2020 · 10.1038/s41375-020-0876-z

• Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)32556-5

• Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1714678

• Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx096

• Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

  New England Journal of Medicine · 2016 · 10.1056/nejmoa1607751

• International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30206-6

• Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2015.61.2267

• Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00464-7

• European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

  Haematologica · 2015 · 10.3324/haematol.2014.117176

• Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1505654

• Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

  Blood · 2015 · 10.1182/blood-2014-12-615187

• Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1402551

• International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70442-5

• Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1411321

• Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70440-1

• Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2013 · 10.1016/s1470-2045(13)70380-2

• New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

  Journal of Clinical Oncology · 2012 · 10.1200/jco.2011.37.7614

• Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

  Blood · 2011 · 10.1182/blood-2010-10-299487

• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  Leukemia · 2011 · 10.1038/leu.2011.196

• Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

  Leukemia · 2010 · 10.1038/leu.2010.60

• International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

  Leukemia · 2008 · 10.1038/leu.2008.307

• Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

  New England Journal of Medicine · 2008 · https://doi.org/10.1056/nejmoa0801479

• Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

  Leukemia · 2007 · 10.1038/sj.leu.2405062

• Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

  New England Journal of Medicine · 2007 · 10.1056/nejmoa070594

• International uniform response criteria for multiple myeloma

  Leukemia · 2006 · https://doi.org/10.1038/sj.leu.2404284

• Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.02.8670

• Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

  Seminars in Oncology · 2003 · 10.1053/sonc.2003.50082

• Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

  New England Journal of Medicine · 1996 · 10.1056/nejm199602223340802

Current projects

No projects listed.